NCT03180944 - Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

December 30, 2018

Conditions

Mucosal IrritationImage Quality

Interventions

DRUG

1.2% Lugol's solution

This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

DRUG

1.0% Lugol's solution

This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

DRUG

0.8% Lugol's solution

This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

DRUG

0.6% Lugol's solution

This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

DRUG

0.4% Lugol's solution

This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

Trial Locations (1)

250012

Qilu Hospital, Shandong University, Jinan

All Listed Sponsors

lead

Shandong University

OTHER